91 related articles for article (PubMed ID: 38553702)
21. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer.
Sirhan Z; Thyagarajan A; Sahu RP
Mil Med Res; 2022 Jul; 9(1):39. PubMed ID: 35820970
[TBL] [Abstract][Full Text] [Related]
22. Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program.
Pellerino A; Soffietti R; Bruno F; Manna R; Muscolino E; Botta P; Palmiero R; Rudà R
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267501
[TBL] [Abstract][Full Text] [Related]
23. Leptomeningeal Carcinomatosis: A Call for Optimizing Diagnostic Sensitivity by the Hematology Laboratory.
Lardinois B; Miller L; Randazzo A; Laurent T; Debois R; Henry S
Case Rep Oncol; 2021; 14(2):1248-1253. PubMed ID: 34703443
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
Brastianos PK; Strickland MR; Lee EQ; Wang N; Cohen JV; Chukwueke U; Forst DA; Eichler A; Overmoyer B; Lin NU; Chen WY; Bardia A; Juric D; Dagogo-Jack I; White MD; Dietrich J; Nayyar N; Kim AE; Alvarez-Breckenridge C; Mahar M; Mora JL; Nahed BV; Jones PS; Shih HA; Gerstner ER; Giobbie-Hurder A; Carter SL; Oh K; Cahill DP; Sullivan RJ
Nat Commun; 2021 Oct; 12(1):5954. PubMed ID: 34642329
[TBL] [Abstract][Full Text] [Related]
25. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Schettini F; Conte B; Buono G; De Placido P; Parola S; Griguolo G; Fabi A; Bighin C; Riccardi F; Cianniello D; De Laurentiis M; Puglisi F; Pelizzari G; Bonotto M; Russo S; Frassoldati A; Pazzola A; Montemurro F; Lambertini M; Guarneri V; Cognetti F; Locci M; Generali D; Conte P; De Placido S; Giuliano M; Arpino G; Del Mastro L
ESMO Open; 2021 Apr; 6(2):100099. PubMed ID: 33819752
[TBL] [Abstract][Full Text] [Related]
26. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Stringer-Reasor EM; May JE; Olariu E; Caterinicchia V; Li Y; Chen D; Della Manna DL; Rocque GB; Vaklavas C; Falkson CI; Nabell LM; Acosta EP; Forero-Torres A; Yang ES
Breast Cancer Res; 2021 Mar; 23(1):30. PubMed ID: 33663560
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
28. Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
Johnson HM; Irish W; Vohra NA; Wong JH
Breast Cancer Res Treat; 2021 Jun; 187(3):805-814. PubMed ID: 33609208
[TBL] [Abstract][Full Text] [Related]
29. Leptomeningeal metastatic cells adopt two phenotypic states.
Remsik J; Chi Y; Tong X; Sener U; Derderian C; Park A; Saadeh F; Bale T; Boire A
Cancer Rep (Hoboken); 2022 Apr; 5(4):e1236. PubMed ID: 33372403
[TBL] [Abstract][Full Text] [Related]
30. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis.
Chi Y; Remsik J; Kiseliovas V; Derderian C; Sener U; Alghader M; Saadeh F; Nikishina K; Bale T; Iacobuzio-Donahue C; Thomas T; Pe'er D; Mazutis L; Boire A
Science; 2020 Jul; 369(6501):276-282. PubMed ID: 32675368
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial.
Seligmann JF; Wright-Hughes A; Pottinger A; Velikova G; Oughton JB; Murden G; Rizwanullah M; Price C; Passant H; Heudtlass P; Marshall H; Johnston S; Dodwell D
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):656-664. PubMed ID: 32600919
[TBL] [Abstract][Full Text] [Related]
32. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Brastianos PK; Lee EQ; Cohen JV; Tolaney SM; Lin NU; Wang N; Chukwueke U; White MD; Nayyar N; Kim A; Alvarez-Breckenridge C; Krop I; Mahar MK; Bertalan MS; Shaw B; Mora JL; Goss N; Subramanian M; Nayak L; Dietrich J; Forst DA; Nahed BV; Batchelor TT; Shih HA; Gerstner ER; Moy B; Lawrence D; Giobbie-Hurder A; Carter SL; Oh K; Cahill DP; Sullivan RJ
Nat Med; 2020 Aug; 26(8):1280-1284. PubMed ID: 32483359
[TBL] [Abstract][Full Text] [Related]
33. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
[TBL] [Abstract][Full Text] [Related]
34. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
Frank S; Carton M; Dubot C; Campone M; Pistilli B; Dalenc F; Mailliez A; Levy C; D'Hondt V; Debled M; Vermeulin T; Coudert B; Perrin C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Patsouris A; Guesmia T; Bachelot T; Robain M; Cottu P
Breast; 2020 Aug; 52():50-57. PubMed ID: 32380440
[TBL] [Abstract][Full Text] [Related]
35. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.
Kumthekar P; Tang SC; Brenner AJ; Kesari S; Piccioni DE; Anders C; Carrillo J; Chalasani P; Kabos P; Puhalla S; Tkaczuk K; Garcia AA; Ahluwalia MS; Wefel JS; Lakhani N; Ibrahim N
Clin Cancer Res; 2020 Jun; 26(12):2789-2799. PubMed ID: 31969331
[TBL] [Abstract][Full Text] [Related]
36. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
37. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Xuhong JC; Qi XW; Zhang Y; Jiang J
Am J Cancer Res; 2019; 9(10):2103-2119. PubMed ID: 31720077
[TBL] [Abstract][Full Text] [Related]
38. A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine.
Nakao T; Okuda T; Fujita M; Kato A
Surg Neurol Int; 2019; 10():131. PubMed ID: 31528467
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging.
Harris P; Diouf A; Guilbert F; Ameur F; Letourneau-Guillon L; Ménard C; Masucci L; Bélair M; Roberge D
Cureus; 2019 Apr; 11(4):e4416. PubMed ID: 31245204
[TBL] [Abstract][Full Text] [Related]
40. The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis.
Maajani K; Jalali A; Alipour S; Khodadost M; Tohidinik HR; Yazdani K
Clin Breast Cancer; 2019 Jun; 19(3):165-177. PubMed ID: 30952546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
